DelveInsight’s “Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Parkinson’s Disease, historical and forecasted epidemiology as well as the Parkinson’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Parkinson’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Parkinson’s Disease Market Forecast

Some of the key facts of the Parkinson’s Disease Market Report: 

• The Parkinson’s Disease market size was valued approximately USD 3,226 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2022, the United States recorded the highest number of diagnosed prevalent cases of Parkinson’s disease, totaling approximately 1,152,195 cases, while Italy reported the lowest incidence, with nearly 152,237 cases.
• In 2022, Parkinson’s disease affected approximately 660,458 males and 491,736 females in the United States. It is projected that the prevalence of the disease will continue to rise by 2032.
• In 2022, Germany recorded the highest number of diagnosed prevalent cases of Parkinson’s disease among EU4 and the UK countries, totaling around 454,448 cases. France followed with approximately 264,695 cases in the same year.
• The analysis suggests that approximately 501,726 cases were diagnosed among individuals aged over 75 years. The majority of cases occur in the elderly population.
• In 2022, the highest prevalence was observed in the stage III group, comprising 587,965 cases, followed by stage IV with 269,729 cases. It is anticipated that the number of cases will rise in the forecast period.
• Key Parkinson’s Disease Companies: AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharmaceutical, Pharma Two B, Jazz Pharmaceuticals, Chase Therapeutics Corporation, Mthera Pharma Co., Ltd., Bial R&D Investments, S.A., Hoffmann-La Roche, NeuroDerm Ltd., Tasly Pharmaceutical, BrainX Corporation, UCB Biopharma SRL, National Neuroscience Institute, GE Healthcare, Cerevel Therapeutics, LLC, Inhibikase Therapeutics, Inc., Bial – Portela C S.A., Neuraly, Inc., Forest Hills Lab, Intra-Cellular Therapies, Inc., FAScinate Therapeutics Inc., AC Immune SA, and others
• Key Parkinson’s Disease Therapies: ABBV-951, ND0612, CVN-424, IPX203, P2B001, Suvecaltamide (JZP385), CTC-413, MT101-5, BIA 28-6156, RO7046015, ND0612, pimavanserin tartrate, Ceftriaxone, UCB0599, Tocovid Suprabio (HOV-12020), Altropane (123I) Injection, Tavapadon, IkT-148009, Opicapone, NLY01, Gemfibrozil, Lenrispodun, KM-819, ACI-7104.056, and others
• The Parkinson’s Disease epidemiology based on gender analyzed that there is male preponderance in the Parkinson’s disease cases in the 7MM
• The Parkinson’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Parkinson’s Disease pipeline products will significantly revolutionize the Parkinson’s Disease market dynamics.

Parkinson’s Disease Overview

Parkinson’s disease is a neurodegenerative disorder that primarily affects movement. It is characterized by a progressive loss of neurons in the brain, particularly in a region called the substantia nigra, which is responsible for producing dopamine, a neurotransmitter involved in movement control.

Get a Free sample for the Parkinson’s Disease Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment

Parkinson’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Parkinson’s Disease Epidemiology Segmentation:

The Parkinson’s Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Parkinson’s Disease
• Prevalent Cases of Parkinson’s Disease by severity
• Gender-specific Prevalence of Parkinson’s Disease
• Diagnosed Cases of Episodic and Chronic Parkinson’s Disease

Download the report to understand which factors are driving Parkinson’s Disease epidemiology trends @ Parkinson’s Disease Epidemiology Forecast

Parkinson’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Parkinson’s Disease market or expected to get launched during the study period. The analysis covers Parkinson’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Parkinson’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Parkinson’s Disease Therapies and Key Companies

• ABBV-951: AbbVie
• ND0612: Mitsubishi Tanabe Pharma(NeuroDerm)
• CVN-424: Cerevance
• IPX203: Amneal Pharmaceutical
• P2B001: Pharma Two B
• Suvecaltamide (JZP385): Jazz Pharmaceuticals
• CTC-413: Chase Therapeutics Corporation
• MT101-5: Mthera Pharma Co., Ltd.
• BIA 28-6156: Bial R&D Investments, S.A.
• RO7046015: Hoffmann-La Roche
• ND0612: NeuroDerm Ltd.
• pimavanserin tartrate: Tasly Pharmaceutical
• Ceftriaxone: BrainX Corporation
• UCB0599: UCB Biopharma SRL
• Tocovid Suprabio (HOV-12020): National Neuroscience Institute
• Altropane (123I) Injection: GE Healthcare
• Tavapadon: Cerevel Therapeutics, LLC
• IkT-148009: Inhibikase Therapeutics, Inc.
• Opicapone: Bial – Portela C S.A.
• NLY01: Neuraly, Inc.
• Gemfibrozil: Forest Hills Lab
• Lenrispodun: Intra-Cellular Therapies, Inc.
• KM-819: FAScinate Therapeutics Inc.
• ACI-7104.056: AC Immune SA

Discover more about therapies set to grab major Parkinson’s Disease market share @ Parkinson’s Disease Treatment Landscape

Parkinson’s Disease Market Drivers

• Growing research and development are increasing the demand for better diagnosis and treatment options for Parkinson’s Disease.
• In recent years, drugs with a novel mechanism of action and combinations are being investigated to overcome the challenges of this entity

Parkinson’s Disease Market Barriers

• The development of a disease-modifying drug can potentially increase the Parkinson’s Disease market share potential.
• In advanced countries, there is a huge annual psychological, social, and economic burden (QALY) due to Parkinson’s Disease.

Scope of the Parkinson’s Disease Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Parkinson’s Disease Companies: AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharmaceutical, Pharma Two B, Jazz Pharmaceuticals, Chase Therapeutics Corporation, Mthera Pharma Co., Ltd., Bial R&D Investments, S.A., Hoffmann-La Roche, NeuroDerm Ltd., Tasly Pharmaceutical, BrainX Corporation, UCB Biopharma SRL, National Neuroscience Institute, GE Healthcare, Cerevel Therapeutics, LLC, Inhibikase Therapeutics, Inc., Bial – Portela C S.A., Neuraly, Inc., Forest Hills Lab, Intra-Cellular Therapies, Inc., FAScinate Therapeutics Inc., AC Immune SA, and others
• Key Parkinson’s Disease Therapies: ABBV-951, ND0612, CVN-424, IPX203, P2B001, Suvecaltamide (JZP385), CTC-413, MT101-5, BIA 28-6156, RO7046015, ND0612, pimavanserin tartrate, Ceftriaxone, UCB0599, Tocovid Suprabio (HOV-12020), Altropane (123I) Injection, Tavapadon, IkT-148009, Opicapone, NLY01, Gemfibrozil, Lenrispodun, KM-819, ACI-7104.056, and others
• Parkinson’s Disease Therapeutic Assessment: Parkinson’s Disease current marketed and Parkinson’s Disease emerging therapies
• Parkinson’s Disease Market Dynamics: Parkinson’s Disease market drivers and Parkinson’s Disease market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Parkinson’s Disease Unmet Needs, KOL’s views, Analyst’s views, Parkinson’s Disease Market Access and Reimbursement 

To know more about Parkinson’s Disease companies working in the treatment market, visit @ Parkinson’s Disease Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Parkinson’s Disease Market Report Introduction

2. Executive Summary for Parkinson’s Disease

3. SWOT analysis of Parkinson’s Disease

4. Parkinson’s Disease Patient Share (%) Overview at a Glance

5. Parkinson’s Disease Market Overview at a Glance

6. Parkinson’s Disease Disease Background and Overview

7. Parkinson’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Parkinson’s Disease 

9. Parkinson’s Disease Current Treatment and Medical Practices

10. Parkinson’s Disease Unmet Needs

11. Parkinson’s Disease Emerging Therapies

12. Parkinson’s Disease Market Outlook

13. Country-Wise Parkinson’s Disease Market Analysis (2019–2032)

14. Parkinson’s Disease Market Access and Reimbursement of Therapies

15. Parkinson’s Disease Market Drivers

16. Parkinson’s Disease Market Barriers

17.  Parkinson’s Disease Appendix

18. Parkinson’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/